Key Takeaways
- • LifeMine Therapeutics raised $263 million across Series D and E rounds ($75 million Series D + $188 million Series E) to advance clinical development of its lead transplantation and immunology therapy, LIFE-001.
- • Series E round was oversubscribed and led by Milky Way Investments with participation from high-profile new investors including Bezos Expeditions, Gates Frontier, and RA Capital Management, alongside existing backers GV, GSK, and ARCH Venture Partners.
- • Capital will fund Phase 2 kidney transplant and Phase 1b islet cell transplant studies for LIFE-001, representing a significant advancement in LifeMine's clinical pipeline focused on precision medicines derived from fungal genomic technology.
- • The funding underscores institutional confidence in LifeMine's Top-Down Drug Discovery platform, which uses digital genomic search technology from fungi to identify next-generation precision medicines for transplantation and immunology indications.
Summary
LifeMine Therapeutics, a Watertown, Massachusetts-based clinical-stage biopharmaceutical company, announced the completion of $263 million in new financing to accelerate clinical development of its lead program and advance its pipeline of transplantation and immunology therapies. The capital raise comprised two sequential rounds: a $75 million Series D with existing investors and LoLa Capital Partners, followed by an oversubscribed $188 million Series E led by Milky Way Investments.
The Series E round attracted significant participation from prominent new investors, including Bezos Expeditions (the family office of Amazon founder Jeff Bezos), Gates Frontier (the investment vehicle of the Gates family), and venture capital firm RA Capital Management. The round also benefited from continued support by existing investors including GV (Google Ventures), LoLa Capital Partners, pharmaceutical giant GlaxoSmithKline, Invus, and ARCH Venture Partners—a roster that reflects confidence in LifeMine's scientific approach and commercial potential.
LifeMine's proprietary platform, termed Top-Down Drug Discovery, leverages digital genomic search technology derived from fungi to source next-generation precision medicines. This differentiated approach positions the company within the broader precision medicine and biotechnology sectors. The newly raised capital will be deployed to support continued clinical development of LIFE-001, the company's most advanced candidate, with planned Phase 2 kidney transplant and Phase 1b islet cell transplant studies. These trials represent meaningful progression toward potential therapeutic applications in high-unmet-need transplantation indications.
The oversubscribed Series E, combined with the preceding Series D, demonstrates institutional appetite for LifeMine's approach and signals confidence among sophisticated investors—including family offices and established venture funds—in the company's ability to advance novel immunology and transplantation therapies. For investors monitoring the clinical-stage biotech landscape, LifeMine's funding trajectory and investor syndicate reflect sustained momentum in precision medicine and cell therapy development.
The Series E round attracted significant participation from prominent new investors, including Bezos Expeditions (the family office of Amazon founder Jeff Bezos), Gates Frontier (the investment vehicle of the Gates family), and venture capital firm RA Capital Management. The round also benefited from continued support by existing investors including GV (Google Ventures), LoLa Capital Partners, pharmaceutical giant GlaxoSmithKline, Invus, and ARCH Venture Partners—a roster that reflects confidence in LifeMine's scientific approach and commercial potential.
LifeMine's proprietary platform, termed Top-Down Drug Discovery, leverages digital genomic search technology derived from fungi to source next-generation precision medicines. This differentiated approach positions the company within the broader precision medicine and biotechnology sectors. The newly raised capital will be deployed to support continued clinical development of LIFE-001, the company's most advanced candidate, with planned Phase 2 kidney transplant and Phase 1b islet cell transplant studies. These trials represent meaningful progression toward potential therapeutic applications in high-unmet-need transplantation indications.
The oversubscribed Series E, combined with the preceding Series D, demonstrates institutional appetite for LifeMine's approach and signals confidence among sophisticated investors—including family offices and established venture funds—in the company's ability to advance novel immunology and transplantation therapies. For investors monitoring the clinical-stage biotech landscape, LifeMine's funding trajectory and investor syndicate reflect sustained momentum in precision medicine and cell therapy development.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.